Market Overview - The Shanghai Composite Index closed at 3865.23 points, with a decline of 0.62% [1] - The total trading volume of A-shares reached 25,965.85 billion yuan [1] Technical Analysis - A total of 114 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Hongxing Co., Ltd. with a distance of -2.60% [1] - Huayi Technology with a distance of -2.54% [1] - Top Group with a distance of -2.48% [1] Individual Stock Performance - Hongxing Co., Ltd. (001209) saw a decline of 2.11% with a trading turnover of 4.66% [1] - Huayi Technology (688071) experienced a drop of 6.84% with a trading turnover of 5.55% [1] - Top Group (601689) fell by 6.13% with a trading turnover of 2.80% [1] - Other notable declines include: - Green Harmonic (688017) down 7.05% [1] - Fangzheng Electric (002196) down 1.99% [1] - Zhongyou Technology (688648) down 5.32% [1] Additional Stock Movements - Several stocks showed minor declines, including: - ST Huayi (600360) down 0.49% [2] - Olin Biotech (688319) down 7.06% [2] - Qinchuan IoT (688528) down 1.43% [2] - Stocks with slight increases include: - Gujing (000596) up 2.81% [2]

Group 1 - The core transaction on October 13 involved a block trade of 457,000 shares of Olin Bio, with a transaction value of 10.0037 million yuan, at a price of 21.89 yuan, representing a discount of 15.06% compared to the closing price of the day [2][3] - In the last three months, Olin Bio has recorded a total of 15 block trades, with a cumulative transaction value of 72.6347 million yuan [2] - The closing price of Olin Bio on the day of the transaction was 25.77 yuan, with a slight increase of 0.08%, and a turnover rate of 0.94% [2] Group 2 - The latest margin financing balance for Olin Bio is 328 million yuan, with an increase of 12.9399 million yuan over the past five days, reflecting a growth rate of 4.10% [3] - Olin Bio was established on December 11, 2009, with a registered capital of 405.9336 million yuan [3]

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-13 | 欧林生物 | 688319 | 21.89 | 1000.37 | 45.7 | 甲万左源证券有限 公司主演逐渐区平 | 广发证券股份有限 公司成都属山大道 | | 10月13日，欧林生物大宗交易成交45.7万股，成交额1000.37万元，占当日总成交额的9.27%，成交价21.89元，较市场收盘价25.77元折价15.06%。 ...

Core Viewpoint - Oulin Biotech's stock has shown a positive trend with a 1.47% increase on October 9, 2023, and significant trading activity in both financing and margin trading [1] Financing Summary - On October 9, 2023, Oulin Biotech had a financing buy-in amount of 26.33 million yuan, with a net buy of 3.36 million yuan after repayments [1] - The total financing and margin trading balance reached 322 million yuan, accounting for 2.88% of the circulating market value, indicating a high level of financing activity compared to the past year [1] - The financing balance is above the 90th percentile of the past year, suggesting strong investor interest [1] Margin Trading Summary - On the same day, Oulin Biotech reported no shares were sold or repaid in margin trading, with a margin balance of 0, indicating a lack of short-selling activity [1] - The margin trading balance is also above the 80th percentile of the past year, reflecting a high level of investor confidence [1] Company Performance Summary - As of June 30, 2023, Oulin Biotech reported a total of 6,521 shareholders, an increase of 4.86% from the previous period, while the average circulating shares per person decreased by 4.63% to 62,169 shares [2] - For the first half of 2025, the company achieved a revenue of 306 million yuan, representing a year-on-year growth of 35.17%, and a net profit attributable to shareholders of 13.20 million yuan, up 147.22% year-on-year [2] Dividend Summary - Since its A-share listing, Oulin Biotech has distributed a total of 15.43 million yuan in dividends [3] Institutional Holdings Summary - As of June 30, 2025, among the top ten circulating shareholders, the fund "Xingquan Helun Mixed A" holds 15.44 million shares, unchanged from the previous period, while "Xingquan Heyi Mixed A" holds 8.92 million shares, also unchanged [3]

中国经济网北京10月9日讯欧林生物(688319.SH)近日披露《关于持股5%以上股东权益变动触及1%刻度 的提示性公告》。 根据减持期间股价均价27.25元计算，上海武山套现总金额约11,997.7281万元。 上海武山为樊绍文、樊钒控制的企业。樊绍文、樊钒为父女关系。 公司实际控制人樊绍文、樊钒以及公司董事陈爱民承诺通过上海武山间接持有的股份不参与本次减持。 本次权益变动为公司控股股东的正常减持，不触及要约收购，亦不会导致公司的控股股东及实际控制人 发生变化，不会对公司治理结构及持续经营产生重大影响。 根据公告，上海武山生物技术有限公司(以下简称"上海武山")于2025年9月4日至2025年9月29日通过集 中竞价交易以及大宗交易方式履行此前披露的减持股份计划，截至公告披露日，本次减持计划尚未实施 完毕。 本次权益变动后，上海武山与一致行动人樊绍文、樊钒合计持有公司的股份数量由11,772.0745万股减少 至11,331.7909万股，占公司总股本的比例由29.00%减少至27.92%，权益变动触及1%刻度。上海武山合 计减持公司股份440.2836万股。 ...

Core Viewpoint - Oulin Biotech plans to issue H-shares and apply for a listing on the Hong Kong Stock Exchange, just weeks after terminating its A-share fundraising plan, indicating a strategic shift in its capital-raising approach [1][9]. Company Overview - Oulin Biotech, led by the father-daughter duo Fan Shaowen and Fan Fan, has become a focal point in the Sichuan capital market, with a market capitalization exceeding 11 billion yuan [4][5]. - The company was founded in 2009 and went public on the Sci-Tech Innovation Board in June 2021 [5][7]. Leadership Background - Fan Shaowen, the 72-year-old founder, has a rich background in the pharmaceutical industry, having previously led several companies to success in the blood products sector before pivoting to human vaccines [5][6]. - Fan Fan, born in 1981, has a diverse educational background, including degrees in hotel management and business management, and has held various roles within the company since joining in 2010 [6][5]. Financial Performance - In the first half of 2025, Oulin Biotech reported revenue of 306 million yuan, a year-on-year increase of 35.17%, and a net profit of approximately 13.2 million yuan, marking a turnaround from losses in the previous year [7][8]. - The company's stock price has seen significant recovery, with a cumulative increase of over 150% this year, bringing its market value back above 10 billion yuan [7][8]. Product Portfolio - Oulin Biotech's main products include adsorbed tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine, with ongoing research into vaccines for "super bacteria" and adult vaccines [7][8]. Recent Developments - The company previously attempted to raise funds through an A-share placement but ultimately decided to terminate the plan due to market conditions, while still proceeding with its vaccine research and production projects [9]. - Recent shareholding changes involved a reduction in the stake held by a major shareholder, Shanghai Wushan, which is controlled by the founding family, indicating ongoing adjustments in ownership structure [13].

Summary of Key Points Core Viewpoint - The recent block trading activity of Oulin Bio indicates significant institutional interest, with a notable discount to the market price, suggesting potential investment opportunities in the stock [2][3]. Trading Activity - On September 30, Oulin Bio had three block trades totaling 321,000 shares, with a total transaction value of 7.28 million yuan, at a price of 22.68 yuan per share, reflecting a discount of 16.62% compared to the closing price [2]. - Over the past three months, Oulin Bio has recorded 14 block trades with a cumulative transaction value of 62.63 million yuan [2]. Market Performance - The closing price of Oulin Bio on the same day was 27.20 yuan, marking a 1.95% increase, with a turnover rate of 1.46% and a total trading volume of 162 million yuan [2]. - The stock experienced a net inflow of 17.01 million yuan in main capital for the day, with a cumulative increase of 3.19% over the past five days and a total net inflow of 15.17 million yuan [2]. Financing Data - The latest margin financing balance for Oulin Bio stands at 313 million yuan, having decreased by 16.62 million yuan over the past five days, representing a decline of 5.04% [3]. Company Background - Oulin Bio was established on December 11, 2009, with a registered capital of 405.93 million yuan [3].

9月30日，欧林生物大宗交易成交32.1万股，成交额728.03万元，占当日总成交额的4.31%，成交价22.68 元，较市场收盘价27.2元折价16.62%。 | 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-30 | 欧林生物 | 688319 | 22.68 | 299.38 | 13.2 | 华泰证券服份有限 公司北京分公司 | 公司日本最出版社 | Ka | | 2025-09-30 | 欧林生物 | 688319 | 22.68 | 226.8 | 10 | 君意義創意參與69 | 合計算出版品 | KI | | 2025-09-30 | 欧林生物 | 688319 | 22.68 | 201.85 | 8 . d | 机构专用 | 公司是在第二次 | 성 | ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-049 成都欧林生物科技股份有限公司关于持股 5%以上股 东权益变动触及 1%刻度的提示性公告 上海武山生物技术有限公司及其一致行动人樊绍文、樊钒保证向本公司提供的信 息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 3.一致行动人信息 关系说明：上海武山生物技术有限公司(以下简称"上海武山")为樊绍文、 樊钒控制的企业。樊绍文、樊钒为父女关系。 二、 权益变动触及 1%刻度的基本情况 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | √控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | - ...

成都欧林生物科技股份有限公司发布公告，其控股股东上海武山生物技术有限公司及其一致行动人樊绍 文、樊钒权益变动触及1%刻度。2025年9月4日 - 29日，上海武山通过集中竞价和大宗交易方式减持股 份，目前减持计划尚未实施完毕。变动后，三者合计持股比例从29.00%降至27.92%，其中仅上海武山 直接持股变动。本次减持是履行此前披露计划，不触及要约收购，不会使控股股东及实控人变化，也不 影响公司治理与经营。信息披露义务人将依规减持并及时披露进展。 ...